ViroGates AS (OCSE:VIRO) Moat Score: 0/10 (As of Jul. 06, 2026)


OCSE:VIRO ViroGates AS OCSE:VIRO
46 GF Score
Price kr10.20
GF Value kr6.76
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is ViroGates AS Moat Score?

ViroGates AS has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

ViroGates AS has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ViroGates AS might have No Moat - No discernible moat.

ViroGates AS  (OCSE:VIRO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

ViroGates AS Moat Score Related Terms

OCSE:VIRO
46GF Score
ViroGates AS OCSE:VIRO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of kr10.20 is trading 50.9% above its estimated GF Value™ of kr6.76. GuruFocus considers ViroGates AS to be Significantly Overvalued.

Key valuation signals for OCSE:VIRO:

  • Moat Score: 0
  • GF Value™: kr6.76 vs. price of kr10.20 (50.9% above fair value)
  • GF Score™: 46/100 with 2 warning signs

No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ViroGates AS Business Description

Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
46GF Score

Get the complete analysis for OCSE:VIRO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.20
Price
kr6.76
GF Value